Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen

Wculek, Stefanie K.; Amores Iniesta, Joaquín; Conde Garrosa, Ruth; Kouili, Sofía C.; Melero, Ignacio; Sancho, David

Publication:
Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen

dc.contributor.author	Wculek, Stefanie K.
dc.contributor.author	Amores Iniesta, Joaquín
dc.contributor.author	Conde Garrosa, Ruth
dc.contributor.author	Kouili, Sofía C.
dc.contributor.author	Melero, Ignacio
dc.contributor.author	Sancho, David
dc.contributor.department	Sanidad Animal
dc.date.accessioned	2024-10-18T06:45:01Z
dc.date.available	2024-10-18T06:45:01Z
dc.date.issued	2019-04-08
dc.description	© The Author(s) 2019. This manuscript version is made available under the CC-BY 4.0 license http://creativecommons.org/licenses/by/4.0/ This document is the Published version of a Published Work that appeared in final form in Journal for ImmunoTherapy of Cancer. To access the final edited and published work see https://doi.org/10.1186/s40425-019-0565-5	es
dc.description.abstract	The manipulation of dendritic cells (DCs) for cancer vaccination has not reached its full potential, despite the revolution in cancer immunotherapy. DCs are fundamental for CD8+ T cell activation, which relies on cross-presentation of exogenous antigen on MHC-I and can be fostered by immunogenic cancer cell death. Translational and clinical research has focused on in vitro-generated monocyte-derived DCs, while the vaccination efficacy of natural conventional type 1 DCs (cDC1s), which are associated with improved anti-tumor immunity and specialize on antigen cross-presentation, remains unknown.	es
dc.format	application/pdf	es
dc.format.extent	16	es
dc.identifier.doi	https://doi.org/10.1186/s40425-019-0565-5
dc.identifier.eisbn	Journal for ImmunoTherapy of Cancer, 2019, Vol. 7 (1) : 100	es
dc.identifier.issn	Electronic: 2051-1426
dc.identifier.uri	http://hdl.handle.net/10201/145401
dc.language	eng	es
dc.publisher	BMJ Publishing Group	es
dc.relation	Work in the DS laboratory is funded by the CNIC and grant SAF2016–79040-R from Ministerio de Ciencia, Innovación e Universidades (MCIU), Agencia Estatal de Investigación and Fondo Europeo de Desarrollo Regional (FEDER); B2017/BMD-3733 Immunothercan-CM from Comunidad de Madrid; RD16/0015/0018-REEM from FIS-Instituto de Salud Carlos III, MICINN and FEDER; Acteria Foundation; Constantes y Vitales prize (Atresmedia); La Marató de TV3 Foundation (201723); and the European Research Council (ERC-2016-Consolidator Grant 725091). Work at the IM laboratory is funded by grants from MCIU (SAF2014–52361-R and SAF2017–83267-C2–1-R) and by European Commission VII Framework and Horizon 2020 programs (AICR), Fundación de la Asociación Española Contra el Cáncer (AECC), and Fundación BBVA. SKW is supported by a European Molecular Biology Organization Long-term Fellowship (grant ALTF 438–2016) and a CNIC-International Postdoctoral Program Fellowship (grant 17230–2016). SCK is a recipient of a FPU fellowship (FPU16/03142) from the Spanish Ministry of Education, Culture and Sports. IM and DS labs are funded by the European Commission (635122-PROCROP H2020). The CNIC is supported by the MCIU and the Pro-CNIC Foundation, and is a Severo Ochoa Center of Excellence (SEV-2015-0505).	es
dc.relation.publisherversion	https://jitc.bmj.com/content/7/1/100.info	es
dc.rights	info:eu-repo/semantics/openAccess	es
dc.rights	Atribución 4.0 Internacional	*
dc.rights.uri	http://creativecommons.org/licenses/by/4.0/	*
dc.subject	Conventional dendritic cells	es
dc.subject	cDC1	es
dc.subject	Cancer immunotherapy	es
dc.subject	Vaccination	es
dc.subject	Cell associated antigen	es
dc.subject	Cross presenting dentritic cells	es
dc.subject	Immunogenic cell death	es
dc.title	Effective cancer immunotherapy by natural mouse conventional type-1 dendritic cells bearing dead tumor antigen	es
dc.type	info:eu-repo/semantics/article	es
dspace.entity.type	Publication	es